Cardiac Complications After SARS-CoV-2 Infection and mRNA COVID-19 Vaccination — PCORnet, United States, January 2021–January 2022

Details

• Journal Article:
  Morbidity and Mortality Weekly Report (MMWR)
• Personal Author:
  Block, Jason P. ; Boehmer, Tegan K. ; Forrest, Christopher B. ; Carton, Thomas W. ; Lee, Grace M. ; Ajani, Umed A. ; Christakis, Dimitri A. ; Cowell, Lindsay G. ; Draper, Christine ; Ghildayal, Nidhi ; Harris, Aaron M. ; Kappelman, Michael D. ; Ko, Jean Y. ; Mayer, Kenneth H. ; Nagavedu, Kshema ; Oster, Matthew E. ; Paranjape, Anuradha ; Puro, Jon ; Ritchey, Matthew D. ; Shay, David K. ; Thacker, Deepika ; Gundlapalli, Adi V.
• Description:
  Cardiac Complications, particularly myocarditis and pericarditis, have been associated with SARS-CoV-2 (the Virus that causes COVID-19) infection (1-3) and mRNA COVID-19 vaccination (2-5). Multisystem inflammatory syndrome (MIS) is a rare but serious complication of SARS-CoV-2 infection with frequent cardiac involvement (6). Using electronic health record (EHR) data from 40 U.S. health care systems during January 1, 2021-January 31, 2022, investigators calculated incidences of cardiac outcomes (myocarditis; myocarditis or pericarditis; and myocarditis, pericarditis, or MIS) among persons aged ≥5 years who had SARS-CoV-2 infection, stratified by sex (male or female) and age group (5-11, 12-17, 18-29, and ≥30 years). Incidences of myocarditis and myocarditis or pericarditis were calculated after first, second, unspecified, or any (first, second, or unspecified) dose of mRNA COVID-19 (BNT162b2 [Pfizer-BioNTech] or mRNA-1273 [Moderna]) vaccines, stratified by sex and age group. Risk ratios (RR) were calculated to compare risk for cardiac outcomes after SARS-CoV-2 infection to that after mRNA COVID-19 vaccination. The incidence of cardiac outcomes after mRNA COVID-19 vaccination was highest for males aged 12-17 years after the second vaccine dose; however, within this demographic group, the risk for cardiac outcomes was 1.8-5.6 times as high after SARS-CoV-2 infection than after the second vaccine dose. The risk for cardiac outcomes was likewise significantly higher after SARS-CoV-2 infection than after first, second, or unspecified dose of mRNA COVID-19 vaccination for all other groups by sex and age (RR 2.2-115.2). These findings support continued use of mRNA COVID-19 vaccines among all eligible persons aged ≥5 years.
• Subjects:
  BNT162 Vaccine COVID-19 COVID-19 Vaccines Female Humans Male Myocarditis Pericarditis RNA, Messenger SARS-CoV-2 Vaccination

  More +
• Source:
  MMWR Morbidity Mortal Weekly Rep. 71(14):517-523
• Series:
  Weekly Report: Morbidity and Mortality Weekly Report (MMWR)
• DOI:
  http://dx.doi.org/10.15585/mmwr.mm7114e1
• ISSN:
  0149-2195 (print) ; 1545-861X (digital)
• Pubmed ID:
  35389977
• Pubmed Central ID:
  PMC8989373
• Document Type:
  Journal Article
• Place as Subject:
  United States
• Pages in Document:
  7 pdf pages
• Volume:
  71
• Issue:
  14
• Collection(s):
  Morbidity and Mortality Weekly Report (MMWR)
• Main Document Checksum:
  urn:sha-512:9760017e10ab0bd5d0a57a218e5d6729c67ca06571b92750a65d06ee738480a55ac756b4d933412b85eb4e2077cd5a5f1e39903babf6049a589cf6bfa82447bf
• Download URL:
  https://stacks.cdc.gov/view/cdc/116620/cdc_116620_DS1.pdf
• File Type:
  [PDF - 139.91 KB ]